Biliary Cancers

Current Location

36 Biliary Cancers Trials Near You

Power is an online platform that helps thousands of Biliary Cancers patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

STAR0602 for Advanced Cancers

Columbus, Ohio
This trial is testing a new drug called STAR0602 to see if it is safe and effective for treating advanced cancers with specific markers. The drug is given through an IV and aims to find and destroy cancer cells by recognizing these markers. The study will first determine the best dose and then see how well the drug works in patients.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

365 Participants Needed

T-DXd + Rilvegostomig for Biliary Tract Cancer

Columbus, Ohio
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

620 Participants Needed

Tucatinib + Trastuzumab for HER2-Positive Cancers

Columbus, Ohio
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant. The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

217 Participants Needed

Dato-DXd Combination Therapy for Advanced Cancers

Columbus, Ohio
This trial is testing Dato-DXd, a targeted cancer treatment, in patients with advanced or metastatic solid tumors. The treatment aims to deliver chemotherapy directly to cancer cells, helping to kill them while reducing harm to healthy cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

582 Participants Needed

Atezolizumab + Varlilumab (+/- Cobimetinib) for Biliary Tract Cancer

Columbus, Ohio
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Varlilumab is an immune agonist antibody that may further strengthen the immune system's attack on the cancer. Cobimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving atezolizumab in combination with varlilumab and cobimetinib may work better than atezolizumab and varlilumab alone in treating patients with unresectable biliary tract cancer.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

57 Participants Needed

Chemotherapy for Biliary Tract Cancer

Columbus, Ohio
This trial is testing how well two cancer-fighting drugs work together, and whether adding a third drug makes them more effective in treating patients with advanced biliary tract cancers. The drugs aim to kill cancer cells, stop them from dividing, or prevent them from spreading.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

452 Participants Needed

Chemotherapy + Binimetinib for Biliary Tract Cancer

Dayton, Ohio
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (advanced) and had progression of cancer after previous treatments (2nd line setting). Fluorouracil is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It works by killing tumor cells. Leucovorin may help the other drugs in the mFOLFOX6 chemotherapy regimen work better by making tumor cells more sensitive to the drugs. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps to stop or slow the spread of tumor cells. Giving binimetinib in combination with mFOLFOX6 chemotherapy may be effective in shrinking or stabilizing advanced biliary tract cancers in the 2nd line setting.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

66 Participants Needed

CTX-009 + Paclitaxel for Biliary Tract Cancer

Canton, Ohio
This trial tests a new drug (CTX-009) combined with chemotherapy in patients with advanced biliary tract cancers who have already had other treatments and cannot have surgery. The treatment aims to boost the immune system and stop cancer cell growth.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3

150 Participants Needed

DB-1303 for Solid Cancers

Canton, Ohio
This trial is testing a new drug called DB-1303 to see if it is safe for patients with advanced solid tumors that express HER2. The study will begin with lower doses and increase them over time to find the highest dose that patients can handle. This helps determine the best dose for future studies.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

766 Participants Needed

S095035 for Advanced Cancer

Maumee, Ohio
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

308 Participants Needed

Larotrectinib for Solid Cancers

Cleveland, Ohio
This trial tests how well larotrectinib works for children and adults with advanced solid tumors that have specific gene changes. The drug blocks the actions of these genes to stop cancer growth.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

215 Participants Needed

Brigimadlin for Solid Cancers

Cleveland, Ohio
This trial is testing a medicine called BI 907828 for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder who have no other treatment options. The medicine is taken as a tablet periodically and works by blocking a protein that helps cancer cells grow.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

99 Participants Needed

ABBV-400 for Advanced Cancer

Cleveland, Ohio
This trial tests ABBV-400, a new drug, on adults with difficult-to-treat cancers. The goal is to see how safe it is and how well it works. Patients will be monitored frequently.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

260 Participants Needed

BAY2927088 for Cancer

Cleveland, Ohio
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how well BAY2927088 (sevabertinib) works in people with different types of solid tumors with HER2 mutations. These include tumors in the colon or rectum, the uterus and the cervix (lower part of the uterus), the bladder, and the biliary tract (includes gall bladder and bile ducts) as well as other types of solid tumors with the exception of people with advanced non-small cell lung cancer (NSCLC). Solid tumors may have specific changes or mutations to a gene called human epidermal growth receptor-2 (HER2). This leads to the formation of an abnormal form of HER2 protein in the cancer cells, resulting in increased cell growth. The study treatment, BAY2927088, is expected to block the abnormal HER2 protein which may stop the spread of cancer. The trial will include about 111 participants who are at least 18 years old. All the participants will take 20 mg of BAY2927088 as tablets by mouth. The participants will take treatments in 3-week periods called cycles. These 3-week cycles will be repeated throughout the trial. The participants can take BAY2927088 until their cancer gets worse, until they have medical problems, or until they leave the trial. During the trial, the doctors will take imaging scans of different parts of the body to study the spread of cancer and will check heart health using echocardiogram or cardiac magnetic resonance imaging (MRI) and electrocardiogram (ECG). The doctors will also take blood and urine samples and do physical examinations to check the participants' health. They will ask questions about how the participants are feeling and if they have any medical problems.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

111 Participants Needed

AMG 193 + Docetaxel for Advanced Solid Cancers

Cleveland, Ohio
This trial tests AMG 193 in adults with advanced cancers. The drug aims to specifically attack these cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

649 Participants Needed

AMG 193 + Other Therapies for Pancreatic Cancer

Cleveland, Ohio
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

188 Participants Needed

Trastuzumab Deruxtecan for Cancer

Muncie, Indiana
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer), B) any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer), C) HER2 IHC 2+ or 1+ endometrial cancer, D) HER2 IHC 2+ or 1+ ovarian cancer, and E) HER2 IHC 2+ or 1+ cervical cancer. Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favorable risk benefit profile in selected HER2-expressing solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

468 Participants Needed

Anticoagulant Flush for Abdominal Cancer

Cleveland, Ohio
The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or "blood thinner" vs. saline a salt water solution as well as the use of a microsieve in order for the doctor to look at the tissue to check the acceptability of the specimens before sending for analysis. You will be randomly assigned (like a flip of a coin) to have either the blood thinner or the salt water solution placed within the needle being used to sample your abdominal tumor and to have either a sieve used or not. You will be one of 42 participants enrolled in this data collection study which includes 1 sites in the United States.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

42 Participants Needed

Rilvegostomig + Chemotherapy for Biliary Tract Cancer

Lexington, Kentucky
This trial is testing a new drug called rilvegostomig to see if it can help prevent biliary tract cancer from coming back after surgery. The study includes patients who have had surgery to remove their cancer but are still at risk of it returning. Rilvegostomig will be used along with standard chemotherapy to see if this combination is more effective.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

750 Participants Needed

Zanidatamab + Standard Therapy for Biliary Tract Cancer

Detroit, Michigan
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

286 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

Ramucirumab/Merestinib + Chemotherapy for Biliary Tract Cancer

Detroit, Michigan
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

309 Participants Needed

Rucaparib + Nivolumab for Biliary Tract Cancer

Ann Arbor, Michigan
This trial tests if using rucaparib and nivolumab together can help patients with Biliary Tract Cancer live longer. Rucaparib stops cancer cells from repairing themselves, and nivolumab boosts the immune system to fight the cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

32 Participants Needed

TIL Therapy for Biliary Tract Cancer

Pittsburgh, Pennsylvania
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

59 Participants Needed

LNCB74 for Cancer

Pittsburgh, Pennsylvania
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

145 Participants Needed

LY3537982 for Cancer

Pittsburgh, Pennsylvania
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

540 Participants Needed

BL-M07D1 for HER2-Positive Cancer

Detroit, Michigan
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

280 Participants Needed

Pain Management for Cancer Surgery

Pittsburgh, Pennsylvania
This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery. This project is considered "Research" and participation is voluntary. Upon enrollment in this study, the research team will collect data from the patient's medical records. The patient will undergo all of the normal testing and procedures required pre-operatively (standard of care). The study team will then randomly assign the patient (like a flip of a coin) to one of three different study arms for pain management during surgery: 1. Laparoscopic Transversus Abdominis Plane Block (LapTAP) with Local Anesthetic (LA) 2. Laparoscopic Transversus Abdominis Plane Block (LapTAP) only 3. Local Anesthetic (LA) only The patient will receive standard pre- and post-operative care according to clinical guidelines (routine care). The study team will collect information from the patient's medical record for the first 24 hours after their surgery and upon discharge. This information will include pain scores, amount of medication required, any side effects the patient may have experienced, and satisfaction with pain control. Participation in the study will end upon discharge from the hospital.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

48 Participants Needed

PT886 for Stomach Cancer

Pittsburgh, Pennsylvania
This trial tests a new drug, PT886, on patients with advanced stomach, gastroesophageal, and pancreatic cancers. Researchers aim to see if it is safe and effective by observing its effects on the body and tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

258 Participants Needed

Sacituzumab Govitecan + Capecitabine for Gastrointestinal Cancer

Detroit, Michigan
This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers after progression on standard therapy, and to assess correlation of outcomes with the biomarker Trop-2.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

20 Participants Needed

BDC-1001 + Nivolumab for Breast Cancer

Detroit, Michigan
This trial tests a new drug, BDC-1001, alone and with another drug, in patients with advanced HER2-positive cancers. BDC-1001 aims to attack cancer cells directly, and the other drug boosts the immune system to fight the cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

175 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Biliary Cancers clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Biliary Cancers clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Biliary Cancers trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Biliary Cancers is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Biliary Cancers medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Biliary Cancers clinical trials?

Most recently, we added Anticoagulant Flush for Abdominal Cancer, BAY2927088 for Cancer and Pain Management for Cancer Surgery to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Osteopenia Clinical Trials

13 Post-Traumatic Stress Disorder Trials near Philadelphia, PA

Top Clinical Trials near Fort Myers, FL

Top Thyroid Cancer Clinical Trials

Top Atopic Dermatitis Clinical Trials

159 Clinical Trials near Boone, NC

Top Clinical Trials near Keller, TX

Top Clinical Trials near Brookline, MA

Top Clinical Trials near Detroit Lakes, MN

Top Clinical Trials near Centralia, IL

Top Prostate Cancer Clinical Trials near Long Beach, CA

Top Clinical Trials near Farmington, CT

By Trial

TY-2136b for Solid Tumors

Dimethyl Fumarate for Multiple Sclerosis

Text Messaging Program for Pregnancy Health

Chocolate Touch Device for Peripheral Arterial Disease

Let's Know! for Speech Delay

Gluten Challenge for Celiac Disease

TAK-861 for Narcolepsy

Resuscitation Methods for Acute Kidney Injury in Liver Cirrhosis

Reduced Radiation + Cisplatin for Oropharyngeal Cancer

SPI+ and CAMS for Suicide Prevention in Teens

Ribociclib + Everolimus for Dedifferentiated Liposarcoma and Leiomyosarcoma

Metabolic Pathway Tracer for Breast Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial